NASHVILLE, Tenn., Aug. 2, 2023
/PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or
the "Company"), a leading global provider of innovative products
and services for the fast growing cell and gene therapy industry,
reproductive medicine and animal health industries, today announced
that the Company will report financial results for the second
quarter ended June 30, 2023 on
Wednesday, August 9, 2023 after U.S.
markets close.
In addition to the earnings release, a document titled "Cryoport
Second Quarter 2023 in Review", providing a review of Cryoport's
financial and operational performance and a general business
update, will be issued at 4:05 p.m. ET on Wednesday, August 9, 2023. The document is
designed to be read in advance of the questions and answers
conference call and will be accessible at
http://ir.cryoport.com/events-and-presentations.
Cryoport management will host a conference call the same day at
5:00 p.m. ET. The conference call
will be in the format of a questions and answers session and will
address questions members of the investment community have
regarding the Company's reported results. A slide deck will
accompany the call.
Conference Call Information
Date:
Wednesday,
August 9, 2023
Time:
5:00 p.m.
ET
Dial-in numbers:
1-888-886-7786 (U.S.),
1-416-764-8658 (International)
Confirmation code: Request the
"Cryoport Call" or Conference ID: 85344190
Live webcast:
'Investor Relations' section at
www.cryoport.com or click here.
Please allow 10 minutes prior to the call to visit this site to
download and install any necessary audio software.
The questions and answers call will be recorded and available
approximately three hours after completion of the live event in the
Investor Relations section of the Company's website
at www.cryoport.com for a limited time. To access the
replay of the questions and answers click here. A dial-in replay of
the call will also be available to those interested, until
August 16, 2023. To access the
replay, dial 1-844-512-2921 (United
States) or 1-412-317-6671 (International) and enter replay
entry code: 85344190#.
About Cryoport, Inc
Cryoport, Inc. (Nasdaq: CYRX), is
a global provider of innovative products and services to the
fast-growing Cell & Gene Therapy industry - enabling the future
of medicine for a new era of life sciences. With 48 strategic
locations covering the Americas, EMEA (Europe, the Middle
East and Africa) and APAC
(Asia Pacific), Cryoport's global
platform provides mission-critical bio-logistics, bio-storage,
bio-processing, and cryogenic systems to the life sciences markets
worldwide.
For more information, visit www.cryoport.com or follow @cryoport
on Twitter at www.twitter.com/cryoport for live updates.
Forward-Looking Statements
Statements in this
press release which are not purely historical, including statements
regarding the Company's intentions, hopes, beliefs, expectations,
representations, projections, plans or predictions of the future,
are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, those related to the
Company's industry, business, long-term growth prospects, plans,
strategies, acquisitions, future financial results and financial
condition, such as the Company's outlook for full year 2023
revenue, the Company's plans and expectations regarding the launch
of new products and services, and the Company's belief that it is
positioned to achieve sustainable, long-term revenue and earnings
growth. It is important to note that the Company's actual results
could differ materially from those in any such forward-looking
statements. Factors that could cause actual results to differ
materially include, but are not limited to, risks and uncertainties
associated with the effect of changing economic conditions,
including as a result of the COVID-19 pandemic and its variants,
supply chain constraints, inflationary pressures, the ongoing war
between Russia and Ukraine and the effects of foreign currency
fluctuations, trends in the products markets, variations in the
Company's cash flow, market acceptance risks, and technical
development risks. The Company's business could be affected by a
number of other factors discussed in the Company's SEC reports,
including in the "Risk Factors" section of its most recently filed
periodic reports on Form 10-K and Form 10-Q, as well as in its
subsequent filings with the SEC. The forward-looking statements
contained in this press release speak only as of the date hereof
and the Company cautions investors not to place undue reliance on
these forward-looking statements. Except as required by law, the
Company disclaims any obligation, and does not undertake to update
or revise any forward-looking statements in this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cryoport-to-report-second-quarter-2023-financial-results-on-august-9-2023-301891302.html
SOURCE Cryoport, Inc.